Accredited Investors Employee Shareholders Institutions Private Companies Who We Serve Trading and InvestingData SolutionsPrivate Asset Custody Institutional TradingForge ProTrade private companies with Forge’s institutional brokerage toolBrowse CompaniesIndividual InvestingForge MarketsFind new private company investment opportunitiesForge DataAnalyze private markets via Forge’s intuitive web applicationForge Private Market IndexMonitor a benchmark for actively traded private companies Forge Accuidity Private Market IndexInvest in an institutionally-managed diversified basket of private companies (QPs only)Self-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRASolutions All InsightsPrivate Market ReportsMarket InsightsBuying and Selling Pre-IPO All ReportsPrivate Market Updates Forge Investment OutlookStartup News and TrendsPrivate Market Data and AnalyticsTech IPO Calendar for 2024Private Market ExplainedBuying Pre-IPO SharesSelling Pre-IPO Shares Glossary Videos FAQsInsights About Us Leadership Investor Relations People & Culture Careers About

Tyra Biosciences Stock

Q: Can you buy Tyra Biosciences stock?

You can no longer buy Tyra Biosciencesstock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.

tyra.bioHealthcare / BioTech & PharmaFounded: 2018Funding to Date: $157.64MM

Tyra Biosciences targets resistance in oncology with purpose built drugs for the benefit of patients.

Learn more about Tyra Biosciences IPO

Company	Sector	IPO Date	IPO Price/Share	Price/Share as of 7/25/24	Since IPO
Tyra Biosciences	Healthcare	9/17/2021	$16	$20.35	27.2%

Round Date	Series	Amount Raised	Post Money Valuation	Price/Share	Lead Investors	Since IPO
3/21	B	$106.2M	$348.3M	$27.43	Nextech Invest, Cormorant Asset Management, BVF Partners, Janus Henderson Investors, Logos, Alta Partners, RA Capital, Boxer Capital, Cannaan	-25.8%
1/20	A	$51.3M	$68.4M	$8.25	Alta Partners, RA Capital Management, Boxer Capital, Canaan	146.7%

Primary round data: Forge Data. Current stock price: Quandl.
Past performance is no guarantee of future results. There can be no assurance that any investment will achieve its objectives or avoid substantial losses.

Tyra Biosciences stock FAQs

Can you buy Tyra Biosciences stock?

You can no longer buy Tyra Biosciences stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.

How to buy Tyra Biosciences stock?

To invest in a private company like Tyra Biosciences through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

Create a free account to access Forge’s marketplace.
Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.

Can you sell Tyra Biosciences stock?

You can no longer sell stock of Tyra Biosciences on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.

How to sell Tyra Biosciences stock?

If you hold private company shares of Tyra Biosciences - whether as an employee or an early investor - Forge can help you sell them.

Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
Indicate your interest to sell your Tyra Biosciences stock on our platform.
Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.

Is Tyra Biosciences a public company?

No, Tyra Biosciences is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.

What is Tyra Biosciences’ stock price?

The stock price of Tyra Biosciences is $12.75 as of 1/18/24.

What is Tyra Biosciences’ stock ticker symbol?

The ticker symbol of Tyra Biosciences is TYRA.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

PR Newswire 09/17/2021

Tyra Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced the closing of its initial public offering of 12,420,000 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase 1,620,000 additional shares, at an initial public offering price of $16.00 per share. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Tyra, were $198,720,000 million. Tyra's common stock is listed on the Nasdaq Global Select Market under the ticker symbol "TYRA."

Browse More Insights

Frequently Asked Questions

Updated on: Jul 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.